GTBP

GT Biopharma, Inc. (GTBP) - 10-Q Summary for Period Ended September 30, 2025

Business Context and Reporting Period

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company developing immune-oncology products based on its proprietary Tri-specific Killer Engager (TriKE®) and Dual Targeting TriKE® platforms. The company operates as a single segment and is currently focused on advancing product candidates GTB-3650 (for AML/MDS) and GTB-5550 (for solid tumors). This report covers the quarterly period ended September 30, 2025, and the nine months ended on that date. The company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by 6% ($0.22 million) for the three months and 36% ($3.77 million) for the nine months ended September 30, 2025, compared to the prior year periods. This reduction was driven primarily by lower research and development costs (down 51% and 46%, respectively) and significant reductions in legal fees.
• Net Loss: Net loss improved by 9% ($0.30 million) for the quarter and 43% ($4.06 million) for the nine-month period compared to the same periods in 2024.
• Liquidity Position: Working capital improved significantly from a deficit of $(1.67) million at December 31, 2024, to a positive $3.00 million at September 30, 2025. This was largely due to a reduction in current liabilities (from $5.90 million to $1.32 million) following the settlement of vendor payables and the reclassification of Series L preferred stock from mezzanine equity to permanent equity.
• Financing Activity: The company raised approximately $7.47 million in net cash from financing activities during the nine months ended September 30, 2025, primarily through the issuance of Series L Convertible Preferred Stock and the exercise of warrants.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: The company has raised substantial doubt about its ability to continue as a going concern. Management states that existing cash resources may not be sufficient to fund operations for one year from the filing date without additional financing. The independent auditor also raised this concern in the 2024 annual report.
• Product Pipeline: Enrollment for the Phase 1 clinical trial of GTB-3650 began in January 2025. The company anticipates submitting an IND application for GTB-5550 in late December 2025 or January 2026.
• Unusual Items:
  • Gain on Settlement: Recorded a $0.998 million gain on the settlement of a vendor payable (legal fees) in March 2025.
  • Warrant Liability: Recognized a $0.244 million gain from the change in fair value of warrant liability for the nine months ended September 30, 2025.
• Legal Proceedings: The company is involved in several legal matters, including arbitration with a former CFO (Ohri Matter) and lawsuits regarding convertible notes (TWF Global, Silberfein, DiPietro, and Werthman Trust matters). The company intends to vigorously defend these claims, believing them to be without merit.
• NASDAQ Compliance: The company regained compliance with the Nasdaq Minimum Stockholders' Equity Requirement in June 2025 after previously receiving a deficiency notice.

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $2.53 million cash balance against the stated burn rate and the timeline for securing additional financing to address the "substantial doubt" regarding going concern status.
• Series L Preferred Stock: Review the terms of the Series L Convertible Preferred Stock, specifically the 10% cumulative dividend rate, the full-ratchet anti-dilution provisions, and the recent conversion price adjustments that significantly increased the number of potential common shares.
• Warrant Overhang: Assess the impact of the 49.46 million warrants outstanding (weighted average exercise price of $1.04) and the potential for further dilution due to anti-dilution triggers.
• Legal Contingencies: Monitor the status of the Ohri arbitration and the convertible note lawsuits, as adverse outcomes could result in significant cash outflows or equity dilution.
• Related Party Transactions: Review the ongoing agreements and payments to Cytovance Biologics, Inc. (a related party) and the University of Minnesota, which represent a significant portion of R&D expenses and accounts payable.